MetaVia Inc.

NasdaqCM:MTVA Stock Report

Market Cap: US$20.2m

MetaVia Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Heon Kim Hyung

Chief executive officer

US$716.4k

Total compensation

CEO salary percentage64.23%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Sep 17
We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Oct 03
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14
Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21
Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

CEO Compensation Analysis

How has Heon Kim Hyung's remuneration changed compared to MetaVia's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$16m

Jun 30 2025n/an/a

-US$18m

Mar 31 2025n/an/a

-US$25m

Dec 31 2024US$716kUS$460k

-US$28m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$174k

-US$12m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$61kn/a

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$29kn/a

-US$15m

Compensation vs Market: Heon Kim's total compensation ($USD716.40K) is about average for companies of similar size in the US market ($USD577.34K).

Compensation vs Earnings: Heon Kim's compensation has been consistent with company performance over the past year.

CEO

Heon Kim Hyung (49 yo)

2.3yrs
Tenure
US$716,404
Compensation

Mr. Hyung-Heon Kim had been Independent Director of MetaVia Inc. (formerly known as NeuroBo Pharmaceuticals, Inc.) since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, Presi...

Leadership Team

NamePositionTenureCompensationOwnership
Heon Kim Hyung
CEO, President & Director2.3yrsUS$716.40kno data
Marshall Woodworth
Chief Financial Officer2.2yrsUS$774.70k0.027%
$ 5.5k
Mi-Kyung Kim
Chief Scientific Officer2.3yrsno datano data
Robert Homolka
Senior Vice President of Clinical Operations2.3yrsno datano data
W. Fang
Consulting Chief Medical Officer & Advisorno datano datano data
Michael Pine
Senior Vice President of Business Development Advisorless than a yearno datano data
2.3yrs
Average Tenure
49yo
Average Age

Experienced Management: MTVA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Heon Kim Hyung
CEO, President & Director4.4yrsUS$716.40kno data
D. Strickland
Independent Director3.9yrsUS$83.85k0.061%
$ 12.4k
Andrew Koven
Independent Chairman of the Board4.4yrsUS$113.85k0.061%
$ 12.4k
Michael Salsbury
Independent Director6yrsUS$71.85k0.072%
$ 14.7k
Roy Freeman
Chairman of Scientific Advisory Boardno datano datano data
Mark Glickman
Independent Director2.6yrsUS$74.85k0.037%
$ 7.5k
Jason Groves
Independent Director6yrsUS$64.85k0.061%
$ 12.4k
James Tursi
Independent Director2.1yrsUS$64.85k0.034%
$ 6.9k
Carel Le Roux
Member of Scientific Advisory Boardno datano datano data
Angela Fitch
Member of Scientific Advisory Boardno datano datano data
Lee Kaplan
Member of Scientific Advisory Boardno datano datano data
4.4yrs
Average Tenure
63.5yo
Average Age

Experienced Board: MTVA's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 11:30
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MetaVia Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Robert LeBoyerLadenburg Thalmann & Company
Aydin HuseynovLadenburg Thalmann & Company